文献速递肝病消化道肿瘤与早癌

非酒精性脂肪性肝病患者肝细胞癌风险

Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.
PubMed 文献 · Gastroenterology · 2018-08-23

该回顾性队列研究纳入美国退伍军人健康管理局130家机构的296,707例非酒精性脂肪性肝病患者及296,707例性别年龄匹配对照,随访至2015年12月31日;非酒精性脂肪性肝病患者肝细胞癌发生率为0.21/1000人年,显著高于对照(0.02/1000人年;HR 7.62;95%CI 5.76-10.09)。

要点

  • 非酒精性脂肪性肝病患者肝细胞癌发生率0.21/1000人年,显著高于匹配对照的0.02/1000人年(HR 7.62;95%CI 5.76-10.09)。
  • 非酒精性脂肪性肝病肝硬化患者肝细胞癌年发生率最高,为10.6/1000人年。
  • 病历回顾中20%的非酒精性脂肪性肝病合并肝细胞癌患者无肝硬化证据。

核心结论

  • 非酒精性脂肪性肝病患者肝细胞癌风险高于一般临床人群,多数肝细胞癌发生于肝硬化患者,且多数非酒精性脂肪性肝病肝硬化患者的肝细胞癌绝对风险高于公认的肝细胞癌监测阈值。

研究设计与样本

  • 回顾性队列研究,纳入美国退伍军人健康管理局130家机构2004年1月1日至2008年12月31日诊断的非酒精性脂肪性肝病患者296,707例及性别年龄匹配的无非酒精性脂肪性肝病对照296,707例,随访至肝细胞癌诊断、死亡或2015年12月31日。

主要发现

  • 随访2,382,289人年,非酒精性脂肪性肝病患者中490例发生肝细胞癌(0.21/1000人年)。
  • 非酒精性脂肪性肝病患者肝细胞癌发生率显著高于对照(0.02/1000人年;HR 7.62;95%CI 5.76-10.09)。
  • 非酒精性脂肪性肝病肝硬化患者肝细胞癌年发生率最高,为10.6/1000人年。
  • 非酒精性脂肪性肝病肝硬化患者肝细胞癌风险根据其他人口学特征范围为1.6至23.7/1000人年,风险最高者为老年西班牙裔肝硬化患者。
  • 病历回顾中20%的非酒精性脂肪性肝病合并肝细胞癌患者无肝硬化证据。

关键数值与推荐

  • 非酒精性脂肪性肝病患者肝细胞癌发生率0.21/1000人年,对照0.02/1000人年(HR 7.62;95%CI 5.76-10.09)。
  • 非酒精性脂肪性肝病肝硬化患者肝细胞癌年发生率10.6/1000人年,根据人口学特征范围1.6至23.7/1000人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are limited data on the risk of hepatocellular cancer (HCC) in patients with non-alcoholic fatty liver disease (NAFLD). We aimed to estimate the risk of incident HCC among patients with NAFLD. METHODS: We conducted a retrospective cohort study from a total of 130 facilities in the Veterans Health Administration. Patients with NAFLD diagnosed between January 1, 2004 and December 31, 2008 were included and followed until HCC diagnosis, death, or December 31, 2015. We also identified a sex- and age-matched control cohort without NAFLD. We ascertained all new HCC cases from the Central Cancer Registry and manual chart reviews. We calculated incidence rates for HCC by NAFLD status, as well as in subgroups of NAFLD patients. We used competing risk models to compare the risk of HCC in patients with NAFLD vs those without NAFLD. We reviewed electronic medical records of all HCC cases that developed in NAFLD patients without cirrhosis. RESULTS: We compared 296,707 NAFLD patients with 296,707 matched controls. During 2,382,289 person-years [PYs] of follow-up, 490 NAFLD patients developed HCC (0.21/1000 PYs). HCC incidence was significantly higher among NAFLD patients vs controls (0.02/1000 PYs; hazard ratio, 7.62; 95% confidence interval, 5.76-10.09). Among patients with NAFLD, those with cirrhosis had the highest annual incidence of HCC (10.6/1000 PYs). Among patients with NAFLD cirrhosis, HCC risk ranged from 1.6 to 23.7 per 1000 PYs based on other demographic characteristics; risk of HCC was the highest in older Hispanics with cirrhosis. In medical record reviews, 20% of NAFLD patients with HCC had no evidence of cirrhosis. CONCLUSIONS: Risk of HCC was higher in NAFLD patients than that observed in general clinical population. Most HCC cases in NAFLD developed in patients with cirrhosis. The absolute risk of HCC was higher than the accepted thresholds for HCC surveillance for most patients with NAFLD cirrhosis.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kanwal F, Kramer JR, Mapakshi S, et al. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018. PMID: 30144434. doi:10.1053/j.gastro.2018.08.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。